EMMPRIN expression in tongue squamous cell carcinoma
- 30 June 2009
- journal article
- research article
- Published by Wiley in Journal of Oral Pathology & Medicine
- Vol. 38 (6) , 518-523
- https://doi.org/10.1111/j.1600-0714.2009.00775.x
Abstract
Extracellular matrix metalloproteinase inducer (EMMPRIN) is identified as a tumor-cell membrane protein that stimulates matrix metalloproteinases (MMPs) production. Several studies have shown that higher EMMPRIN expression is associated with shorter survival time and correlated significantly with more advanced clinico-parameters of cancer. The aim of this study was to investigate the relationship between clinico-pathologic characteristics and EMMPRIN, and prognostic significance of EMMPRIN expression in human tongue squamous cell carcinoma. Extracellular MMP inducer expression was examined immunohistochemically on paraffin-embedded tissue specimens from 68 patients with tongue squamous cell carcinoma and who underwent radical surgeries from 1996 to 2006. The 68 patients were followed up from 1 to 119 months, with an average of 27.5 months. Nonparametric tests were performed for the comparison of EMMPRIN expression between two independent groups. Survival analysis was performed to find the prognostic significance of EMMPRIN expression. We found that EMMPRIN expression in tongue squamous cell carcinoma is significantly higher than that in non-cancerous epithelium adjacent to carcinoma of tongue. In addition, EMMPRIN expression is significantly associated with tumor diameter and clinical stage in the samples, but did not correlate with gender, age, tumor metastasis, and pathological grade. Finally, survival analysis indicates that EMMPRIN overexpression correlates significantly with poor overall survival in the patient cohort. These results suggest that EMMPRIN might represent an attractive target for immunotherapeutic approaches in a subgroup of patients with tongue squamous cell carcinoma.Keywords
This publication has 24 references indexed in Scilit:
- EMMPRIN mediates β-adrenergic receptor-stimulated matrix metalloproteinase activity in cardiac myocytesJournal of Molecular and Cellular Cardiology, 2008
- EMMPRIN and fascin overexpression associated with clinicopathologic parameters of pancreatobiliary adenocarcinoma in Chinese peopleAPMIS, 2007
- EpCAM expression in squamous cell carcinoma of the oral cavity: Frequency and relationship to clinicopathologic featuresOral Oncology, 2007
- Extracellular Matrix Metalloproteinase Inducer Up-regulates the Urokinase-Type Plasminogen Activator System Promoting Tumor Cell InvasionCancer Research, 2007
- Extracellular Matrix Metalloproteinase Inducer Stimulates Tumor Angiogenesis by Elevating Vascular Endothelial Cell Growth Factor and Matrix MetalloproteinasesCancer Research, 2005
- Emmprin Promotes Anchorage-Independent Growth in Human Mammary Carcinoma Cells by Stimulating Hyaluronan ProductionCancer Research, 2004
- EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma.Clinical & Experimental Metastasis, 2003
- Oral Cancer and Precancerous LesionsCA: A Cancer Journal for Clinicians, 2002
- Analysis of Treatment Results for Oral Tongue CancerThe Laryngoscope, 2002
- Expression of EMMPRIN by oral squamous cell carcinomaInternational Journal of Cancer, 2000